Decentralized Trials Guidance May Reflect US FDA’s Lessons Learned During COVID-19
Executive Summary
Work on guidance that was originally expected in 2020 continues as the agency and industry learn more about the utility and spectrum of decentralized trials as a result of the novel coronavirus pandemic.
You may also be interested in...
Decentralized Clinical Trials Could Affect Validity Of Non-Inferiority Finding, US FDA Says
Draft guidance notes that data obtained from a decentralized clinical trial may be less precise than that from a site-based trial, creating challenges in calculating a non-inferiority margin. FDA specifies what should be included in DCT data management, trial monitoring and safety monitoring plans.
New Global Alliance To Drive Momentum On Decentralized Trials
A new multi-stakeholder alliance wants to improve the adoption of decentralized clinical trials that have already drawn much attention during the COVID-19 pandemic. There are plans to aggregate best practices, share evidence and information, and identify and address key barriers.
Global CRO Body Facilitates Further Uptake Of Decentralized Trials
The international association of contract research organizations, ACRO, has developed a toolkit that it hopes will propel greater adoption of decentralized clinical trials.